Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain

Current Medical Research and Opinion

Volumn 27, Issue 9, 2011, Pages 1693-1703

  Silverstein, Steven M ^a   Cable, Melissa G ^b   Sadri, Ehsan ^c   Peace, James H ^d   Fong, Raymond ^e   Chandler, Simon P ^f   Gow, James A ^f   Klier, Sharon M ^f   McNamara, Timothy R ^f  

^a Silverstein Eye Centers   (United States)

^b Discover Vision Centers   (United States)

^c Atlantis Eye Care   (United States)

^d Diabetic Eye Medical Clinic   (United States)

^e Raymond Fong Eye Care   (United States)

^f ISTA Pharmaceuticals Inc   (United States)

Author keywords

Bromfenac; Cataract surgery; Non steroidal anti inflammatory; Ocular inflammation; Ocular pain; Ophthalmic

Indexed keywords

BROMFENAC; PLACEBO;

ABNORMAL SENSATION; ARTICLE; BLURRED VISION; CATARACT EXTRACTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE INFLAMMATION; EYE PAIN; FOREIGN BODY SENSATION; HUMAN; MULTICENTER STUDY (TOPIC); POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPHENONES; BROMOBENZENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EYE DISEASES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PAIN, POSTOPERATIVE; PLACEBOS; POSTOPERATIVE COMPLICATIONS;

EID: 80051742508     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.597663     Document Type: Article

References (27)

1. Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004;122:487-494 (Pubitemid 38456283)
2. Williams A, Sloan FA, Lee PP. Longitudinal rates of cataract surgery. Arch Ophthalmol 2006;124:1308-1314 (Pubitemid 44379865)
3. Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007;67:1291-308 (Pubitemid 46879095)
4. Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009;3:199-210
5. Guex-Crosier Y. [Non-steroidal anti-inflammatory drugs and ocular inflammation]. Klin Monbl Augenheilkd 2001;218:305-308 (Pubitemid 32537981)
6. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Survey of ophthalmology 2010;55:108-133
7. Friedlaender MH. Corticosteroid therapy of ocular inflammation. Int Ophthalmol Clin 1983;23:175-182
8. Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995;113:725-727
9. ISTA Pharmaceuticals, Inc. Xibrom (bromfenac ophthalmic solution) 0.09% Package Insert, 2010
10. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491
11. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000;27:558-562 (Pubitemid 30418006)
12. Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006;46:21-40 (Pubitemid 44632206)
13. Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007;114:1653-1662
14. Stewart RH, Grillone LR, Shiffman ML, et al. The systemic safety of bromfenac ophthalmic solution 0.09%. J Ocul Pharmacol Ther 2007;23:601-612 (Pubitemid 350204679)
15. Walsh DA, Moran HW, Shamblee DA, et al. Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. J Med Chem 1984;27:1379-1388 (Pubitemid 15200556)
16. Smyth EMBA, FitzGerald GA. Lipid-Derived Autacoids: Eicosanoids and Platelet-Activating Factor, 11th edn. New York, NY: McGraw-Hill, 2006
17. Kida T, Ogawa T, McNamara TR, et al. Evaluations of the human COX-2 inhibition for amfenac, bromfenac, diclofenac, and ketorolac. 33rd Symposium on Cataract, IOL, and Refractive Surgery of the American Society of Cataract and Refractive Surgery, April 27-May 1, 2007, San Diego, CA, USA
18. Co SP. Bronuck Ophthalmic Solution 0.1% Package Insert. Osaka, Japan, 2009
19. ISTA Pharmaceuticals Inc. Data on file
20. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112:953-961 (Pubitemid 40797446)
21. Ikeda H, Sato M, Tsukamoto H, et al. [Evaluation and multivariate statistical analysis of factors influencing patient adherence to ophthalmic solutions]. Yakugaku Zasshi 2001;121:799-806 (Pubitemid 33043399)
22. Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 2008;24:392-398
23. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-540
24. Cha SH, Lee JS, Oum BS, et al. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol 2004; 32:180-184
25. Alcon Laboratories. Nevanac (nepafenac ophthalmic suspension) 0.1% Package Insert. Fort Worth, TX, USA, 2008
26. Allergan, Inc. Acuvail (ketorolac tromethamine ophthalmic solution) 0.45% Package insert, Irvine, CA, USA, 2009
27. ISTA Pharmaceuticals, Inc. Bromday (bromfenac ophthalmic solution) 0.09% Package Insert. Irvine, CA, USA, 2010